Comparative Pharmacology
Head-to-head clinical analysis: FLUOTREX versus PALSONIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOTREX versus PALSONIFY.
FLUOTREX vs PALSONIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The active metabolite of FLUOTREX, 5-fluorouracil (5-FU), inhibits thymidylate synthase, leading to depletion of thymidine triphosphate and inhibition of DNA synthesis. Additionally, it incorporates into RNA, disrupting RNA function.
Selective serotonin reuptake inhibitor (SSRI) that enhances serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing extracellular serotonin levels in the brain.
20 mg/m2 intramuscularly once weekly, not to exceed 30 mg/m2 per week.
70 mg/m2 IV every 3 weeks. Infusion over 60 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10-15 hours, necessitating dose adjustment.
Terminal half-life 12 hours (range 10–14 h) in healthy adults; prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion as unchanged drug (approximately 60-70% of administered dose), with the remainder eliminated via biliary/fecal routes (20-30%) and minor metabolic clearance.
Renal: 65% unchanged; biliary/fecal: 30% as metabolites; 5% other
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid